Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Medpace Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Medpace Holdings's regulatory disclosures and financial reporting.
Medpace Holdings (MEDP) CEO and 10% owner August J. Troendle reported open‑market stock sales. On 11/14/2025, he sold 14,747 shares of Medpace common stock at a weighted average price of $595.26 per share, followed by a sale of 6,047 shares on 11/17/2025 at a weighted average price of $591.00 per share. The sales were executed pursuant to a limit order placed during an open trading window. After these transactions, he beneficially owns 893,368 shares directly and 4,733,019 shares indirectly through Medpace Investors, LLC, where he is the sole manager and controlling unit holder.
Medpace Holdings (MEDP) insider activity: August J. Troendle, CEO, director and 10% owner, reported open‑market sales of common stock executed via a limit order during an open window period. On 11/12/2025, he sold 5,312 shares at a weighted average price of $603.23. On 11/13/2025, he sold 5,128 shares at a weighted average price of $601.37.
After these transactions, he directly owned 914,162 shares. He also reports indirect beneficial ownership of 4,733,019 shares through Medpace Investors, LLC, over which he has voting and investment control, while disclaiming beneficial ownership beyond his pecuniary interest.
Medpace Holdings, Inc. (MEDP) disclosed an insider sale by an executive officer. Exec. VP, Operations Susan E. Burwig sold 18,000 shares of common stock on 11/11/2025 at a price of $605 per share (Transaction Code S). Following the sale, she beneficially owns 47,500 shares, held directly.
The filing notes the trade was executed via a limit order during an open window period.
Medpace Holdings (MEDP) insider transaction: President Jesse J. Geiger reported selling 21,503 shares of common stock on 11/05/2025. The weighted average sale price was $595.66 per share, with individual trades executed between $588.64 and $599.86. Following these transactions, he reported beneficial ownership of 15,000 shares, held directly.
The filing notes the sales were made under a Rule 10b5-1 trading plan adopted on August 6, 2025.
Medpace Holdings, Inc. (MEDP) reported an insider transaction by Director Fred B. Davenport, Jr. on 10/30/2025. He exercised a stock option to acquire 6,472 shares of common stock at an exercise price of $54.99 (code M), then sold 5,972 shares at a weighted average price of $581.88 in trades ranging from $580.53 to $585.26 (code S).
Following these transactions, he directly held 3,498 shares of MEDP common stock and indirectly held 2,000 shares through a trust. The exercised option covered 6,472 underlying shares and had fully vested on May 14, 2020, with an option expiration of May 17, 2026. After the exercise, 0 derivative securities remained beneficially owned.
Medpace Holdings (MEDP) disclosed insider transactions by President Jesse J. Geiger. On 10/27/2025, he exercised 19,460 stock options at $166.73 per share and sold 19,460 shares at a $605.12 weighted average price, with trades ranging from $600.00 to $610.66. On 10/29/2025, he exercised an additional 3,568 options at $166.73 and sold 3,568 shares at $585.
The option was reported as having vested in full on October 27, 2025. Following the transactions, 36,503 shares were reported as beneficially owned directly. The filing notes the sales were effected pursuant to a limit order placed during an open window period.
Medpace Holdings (MEDP): Form 4 insider transaction — On 10/27/2025, General Counsel & Corp. Secy. Stephen P. Ewald exercised 18,230 employee stock options at $166.73 and sold 15,230 shares of common stock at a weighted average price of $598.85 (transactions ranged from $596.25 to $602.955). Following these transactions, he beneficially owned 13,343 shares directly. The option was reported to have vested in full on October 27, 2025, and the derivative position was reduced to 0; the option carried an expiration date of 10/27/2026.
Medpace Holdings (MEDP): insider transaction — An executive officer sold common stock. On 10/27/2025, the Executive Vice President, Operations sold 2,000 shares in an open market transaction at a weighted average price of $605.01, with individual trades ranging from $605.00 to $605.13. The sale was executed via a limit order during an open window period. Following the sale, the officer beneficially owns 65,500 shares, held directly.
Medpace Holdings, Inc. reported strong quarterly results in its Q3 2025 10‑Q. Revenue reached $659.9 million, up 23.7% year over year, driven by growth in Metabolic, Oncology and CNS. Net income was $111.1 million and diluted EPS was $3.86. Operating income rose to $141.8 million as total operating expenses increased with higher reimbursed out‑of‑pocket and personnel costs.
For the first nine months, revenue was $1.82 billion with net income of $316.0 million and diluted EPS of $10.64. Operating cash flow was $520.6 million, while share repurchases totaled $912.9 million year to date, contributing to a decline in cash and equivalents to $285.4 million from $669.4 million at year‑end. The company ended the quarter with $3,000.6 million in backlog and net new awards of $789.6 million in Q3. The effective tax rate was 22.2% in the quarter, reflecting lower FDII benefits.
As of October 17, 2025, common shares outstanding were 28,168,223. The unsecured credit facility remained undrawn with $10.0 million available.
Medpace Holdings, Inc. furnished an 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference.
The company states the information in Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" under the Exchange Act. MEDP’s common stock trades on the NASDAQ Global Select Market.